Universitaetsklinikum Heidelberg AöR
Universitaetsklinikum Heidelberg AöR is recorded as a service provider in 42 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 42 trials · Latest update first
Local Tenecteplase ApplicatiOn subsequent to endovasCular Recanalization in Anterior CircuLation Stroke-the LOCAL trial
Sponsor Universitaetsklinikum Heidelberg AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
PD-1 blockade alone versus in combination with chemotherapy as first line therapy in females with advanced NSCLC & PD-L1 expression ≥50%
Sponsor Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia
Sponsor University Hospital Of Ulm AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Prospective, Open-Label, Multicenter, Randomized, Phase 3 Trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVe) Compared to Obinutuzumab and Venetoclax (GVe) in Previously Untreated Patients with High Risk Chronic Lymphocytic Leukemia (CLL): The CLL16-TRIAL OF THE GCLLSG
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)
Sponsor Universitaetsklinikum Heidelberg AöR
- Start (EU)
- Latest update
- Estimated end
IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma
Sponsor Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP 101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
Sponsor Heidelberg Pharma AG
- Start (EU)
- Latest update
- Estimated end
International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
(20186 - FIONA OLE) An 18-month, open-label, single-arm safety extension study of an age-and bodyweight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature (ESPAC-6)
Sponsor Universitaetsklinikum Heidelberg AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
(19920) A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
A phase II, multicenter, 1:1 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of bolus application of Cyclosporine A (CsA) or Placebo in patients with Takotsubo syndrome. (Cyclosporine In Takotsubo syndrome (CIT))
Sponsor Universitaetsklinikum Heidelberg AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
EORTC 2334-BTG: [177Lu]Lu-DOTATATE for recurrent MENingioma (LUMEN-1): a randomized phase II study
Sponsor Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
- Start (EU)
- Latest update
- Estimated end
- Not reported
Enhancing social skills in schizophrenia spectrum disorders – two-arm, double-blind, randomized clinical trial investigating oxytocin vs. placebo as an add-on to an individualized psychosocial treatment (OXY-APS)
Sponsor Zentralinstitut Fuer Seelische Gesundheit
- Start (EU)
- Latest update
- Estimated end
- Not reported
A prospective randomized single blind multicentre phase II study of organ perfusion with Custodiol-N compared with Custodiol in heart transplantation in children.
Sponsor Dr. Franz Koehler Chemie GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including a randomized phase III study evaluating the non-inferiority of three courses of high-dose chemotherapy (HDCT) compared to focal radiotherapy as consolidation therapy
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT)
Sponsor Heidelberg University Hospital AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
EORTC-2427-BTG: Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)
Sponsor Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
- Start (EU)
- Latest update
- Estimated end
A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator’s choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy
Sponsor Universitaetsklinikum Heidelberg AöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Universitaetsklinikum Heidelberg AöR?
The 2026-10-09 snapshot links Universitaetsklinikum Heidelberg AöR to 42 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Clinical monitoring, Project management, Regulatory services, among 27 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universitaetsklinikum Heidelberg AöR?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Neurology, Haematological Malignancies, Cardiology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universitaetsklinikum Heidelberg AöR conducted?
The linked trials record locations in 21 countries, including Germany, Austria, Spain, France, Denmark. These are trial locations, not confirmed office locations or countries where Universitaetsklinikum Heidelberg AöR delivered services.
What can this page tell me about Universitaetsklinikum Heidelberg AöR's trial experience?
Browse 42 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universitaetsklinikum Heidelberg AöR. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universitaetsklinikum Heidelberg AöR